Emergent BioSolutions Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 11/11/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $742.9M | $1.0B | $1.0B | $1.1B | — |
| Cost of revenue | $326.2M | $681.3M | $705.4M | $693.1M | — |
| Gross profit | — | — | $317.6M | $383.0M | — |
| Selling, general & administrative | $186.1M | $308.0M | $368.4M | $339.5M | — |
| Research and development | $53.2M | $70.7M | $111.4M | $188.3M | — |
| Operating income | $100.1M | -$108.7M | -$726.4M | -$170.0M | — |
| Interest expense | $59.3M | $71.0M | $87.9M | $37.3M | — |
| Pretax income | $82.8M | -$142.9M | -$731.2M | -$219.0M | — |
| Income tax expense | $30.2M | $47.7M | $29.3M | -$7.4M | — |
| Net income | $52.6M | -$190.6M | -$760.5M | -$211.6M | — |
| Balance Sheet | |||||
| Cash and equivalents | $205.4M | $99.5M | $111.7M | $642.6M | — |
| Current assets | $662.5M | $598.7M | $679.5M | $1.2B | — |
| Total assets | $1.3B | $1.4B | $1.8B | $3.2B | — |
| Current liabilities | $132.2M | $162.4M | $651.3M | $1.2B | — |
| Total liabilities | $796.0M | $906.9M | $1.2B | $1.8B | — |
| Stockholders' equity | $522.6M | $482.8M | $649.3M | $1.4B | — |
| Cash Flow Statement | |||||
| Cash from operations | $170.6M | $58.7M | -$206.3M | -$34.1M | — |
| Depreciation and amortization | $95.8M | $108.8M | $125.1M | $143.3M | — |
| Stock-based compensation | $16.2M | $18.0M | $23.1M | $45.1M | — |
| Capital expenditure | $13.8M | $22.9M | $51.6M | $115.8M | — |
| Free cash flow | $156.8M | $35.8M | -$257.9M | -$149.9M | — |
| Share repurchases | $24.9M | $0 | $0 | $82.1M | $187.9M |
| Impairments | $0 | $0 | $218.2M | $6.7M | — |
Shares outstanding 51.6M · Free float 12.3%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.